TTUHSC’s Andrey Karamyshev, Ph.D., received a two-year grant from the National Cancer Institute to investigate new approaches to inhibit STAT3, a protein associated with approximately 70% of all human ...

Researchers have reported results from the first-ever clinical trial of a new class of targeted therapy in pet cats with head and neck squamous cell carcinoma (HNSCC)—a cancer which is notoriously ...

Immunotherapy uses a person’s own immune system to fight cancer. Immune checkpoint inhibitors are one class of immunotherapy that block specific proteins from slowing the immune response. As a result, ...

VVD-130850 is an investigational oral small molecule inhibitor of STAT3 transcription factor developed for treatment of advanced solid and hematologic tumors as a single agent and in combination with ...